The data demonstrated significant efficacy and no serious adverse events using the StemSpine ultrasound guided non-surgical procedure for treating chronic lower back pain.
The StemSpine procedure using AlloStem resulted in a greater than 90% reduction in narcotic usage, greater than 80% reduction in pain score, and greater than 50% reduction in the Oswestry Score in the treated patients. No patients required re-dosage or surgical intervention at the primary end point of six months and there were no safety related concerns.
StemSpine using AlloStem is a patented procedure that utilizes an 'off the shelf, ready-to-use' universal and proprietary allogenic (donor) cell developed by the Company and trademarked as AlloStem. The patent issued to StemSpine includes both the use of autologous (from the patient) and allogenic (universal donor) cells. In
'To our knowledge, this pilot study is the first to demonstrate safety and clinical efficacy of injecting AlloStem in areas surrounding the disc, thereby potentially repairing, remodeling, and improving the blood supply around the disc and lower back area,' said
About
Forward Looking Statements
This news release may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming clinical trials and laboratory results, marketing efforts, funding, etc. Forward-looking statements address future events and conditions and, therefore, involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements.
Contact:
Email: IR@CreativeMedicalTechnology.com
(C) 2023 Electronic News Publishing, source